论文部分内容阅读
目的:探讨高通量血液透析联合左卡尼汀改善尿毒症患者贫血的临床价值。方法:选择2013年1月至2015年3月间于我院进行治疗的尿毒症患者98例作为研究对象,并分为观察组50例及对照组48例。观察组患者进行高通量血液透析联合左卡尼汀治疗,对照组患者仅进行高通量血液透析治疗。对两组患者治疗前后血常规、生化指标、治疗效果以及不良反应进行观察与比较。结果:治疗前两组患者血常规及生化指标均无明显差异(P>0.05),治疗后两组血常规指标有所提高,生化指标有所下降,均较治疗前差异显著(P<0.05)。除治疗当月两组患者血红蛋白(Hb)及红细胞比容(HCT)差异不显著外,其他时间点观察组各指标均显著优于对照组(P<0.05)。观察组患者治疗总有效率(86.00%)显著高于对照组(68.75%)。两组不良反应发生率无显著差异(P>0.05)。结论:高通量血液透析联合左卡尼汀对于改善尿毒症患者贫血症状疗效显著,安全性高,值得临床推广应用。
Objective: To investigate the clinical value of high-throughput hemodialysis combined with levocarnitine in the treatment of anemia in patients with uremia. Methods: A total of 98 patients with uremia who were treated in our hospital from January 2013 to March 2015 were selected as study subjects and divided into observation group (50 cases) and control group (48 cases). Patients in the observation group were treated with high-throughput hemodialysis combined with levocarnitine, while patients in the control group were treated with high-throughput hemodialysis only. Two groups of patients before and after treatment of blood, biochemical indicators, treatment and adverse reactions were observed and compared. Results: There were no significant differences in blood and biochemical indexes between the two groups before treatment (P> 0.05). After treatment, the blood parameters and the biochemical indexes of the two groups were both improved (P <0.05) . Except for the difference of hemoglobin (Hb) and hematocrit (HCT) between the two groups in the month of treatment, there was no significant difference between the two groups (P <0.05). The total effective rate of observation group patients (86.00%) was significantly higher than the control group (68.75%). No significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: High-throughput hemodialysis combined with levocarnitine has obvious curative effect on the improvement of anemia symptoms in patients with uremia, which is safe and worthy of clinical application.